Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers

Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.

(2023) Joshua E. Reuss et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities

(2023) Liang Chang et al.   NATURE GENETICS

Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients

(2022) G. Hua et al.   ESMO Open

Thinking Differently about Cancer Treatment Regimens

(2021) Jeff Settleman et al.   Cancer Discovery

Acquired Resistance to KRASG12C Inhibition in Cancer

(2021) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer

(2021) Pınar Özden Eser et al.   Science Translational Medicine

In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma

(2016) C Ambrogio et al.   ONCOGENE

Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency

(2015) M Ceccon et al.   ONCOGENE

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

(2015) Arun M Unni et al.   eLife

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE